For its second fiscal quarter (ending June 30), OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) has reported E.P.S. of $2.16 compared to $1.41 a year ago. E.P.S. were $6.24 for the latest four quarters through June 30 versus $5.13 for the same period a year ago.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock suffered a large decline of -8.5% on 7/31/24. The stock closed at $261.75. Moreover, trading volume in this decline was unusually high at 182% of normal. The stock has been strong relative to the market over the last nine months but has declined -5.9% during the last week.
Current PriceTarget Research Rating
VRSK is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
VERISK ANALYTICS INC has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. VERISK ANALYTICS INC has a slightly negative Appreciation Score of 35 but a slightly positive Power Rating of 61, leading to the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment